Home › NDC Lookup › RxCUI directory › RxCUI 2046579

Abiraterone acetate 125 MG Oral Tablet — RxCUI 2046579

RxNorm drug concept · Semantic clinical drug
RxCUI 2046579 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2046579
Official nameAbiraterone acetate 125 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Abiraterone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats prostate cancer that has spread. Abiraterone acetate tablets, Abirtega and Zytiga are used for metastatic castration-resistant and metastatic high-risk castration-sensiti...
  • Take it once a day and swallow the tablets whole with water. With abiraterone acetate tablets, Abirtega or Zytiga, don't eat for 2 hours before or 1 hour after your dose, because f...
  • How should I take it, and does food matter?
  • Abiraterone can cause a hormone imbalance, leading to high blood pressure, low potassium and fluid retention. The steroid is part of your treatment. Don't skip it or stop suddenly,...
📖 Read our full Abiraterone guide →

🕸️ Concept Web — How Abiraterone acetate 125 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abiraterone acetate 125 MG Oral Tablet RxCUI 2046579

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Abiraterone 1100072
    • Abiraterone acetate 1100071
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Yonsa 2046580
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Abiraterone Oral Tablet 1100074
    • Abiraterone acetate Oral Tablet 2646523
    • Abiraterone Oral Product 1163656
    • Abiraterone Pill 1163657
    • Abiraterone acetate Oral Product 2661457
    • Abiraterone acetate Pill 2662678
    • Abiraterone Oral Tablet [Yonsa] 2046582
    • Abiraterone acetate Oral Tablet [Yonsa] 2657815
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abiraterone acetate 125 MG SCDC · 2046578
  • Abiraterone Oral Tablet SCDF · 1100074
  • Abiraterone acetate Oral Tablet SCDFP · 2646523
  • Abiraterone Oral Product SCDG · 1163656
  • Abiraterone Pill SCDG · 1163657
  • Abiraterone acetate Oral Product SCDGP · 2661457
  • Abiraterone acetate Pill SCDGP · 2662678

Brand-Name Concepts

  • Abiraterone acetate 125 MG Oral Tablet [Yonsa] SBD · 2046585
  • Abiraterone acetate 125 MG [Yonsa] SBDC · 2046581
  • Abiraterone Oral Tablet [Yonsa] SBDF · 2046582
  • Abiraterone acetate Oral Tablet [Yonsa] SBDFP · 2657815
  • Yonsa Oral Product SBDG · 2046583
  • Yonsa Pill SBDG · 2046584
  • Yonsa BN · 2046580

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2046579 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
47335-0401-81 120 TABLET in 1 BOTTLE, PLASTIC (47335-401-81) YONSA Sun Pharmaceutical Industries, Inc. 2018-05-22
51407-0503-12 120 TABLET in 1 BOTTLE, PLASTIC (51407-503-12) ABIRATERONE ACETATE Golden State Medical Supply, Inc. 2025-09-04
Observed labelers: Golden State Medical Supply, Inc. (1) · Sun Pharmaceutical Industries, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.